Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation

Abstract Background Semantic variant primary progressive aphasia (svPPA) is generally sporadic, with very few reports of tau pathology caused by MAPT mutations. Methods A 64-year-old man was diagnosed with svPPA with MAPT P301L mutation. Clinical information, cognitive and language functions, multim...

Full description

Bibliographic Details
Main Authors: Jing Xu, Yanmin Xia, Meng Meng, Fang Liu, Ping Che, Yanxin Zhang, Ying Wang, Li Cai, Wen Qin, Nan Zhang
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13195-023-01176-y
_version_ 1811175988408614912
author Jing Xu
Yanmin Xia
Meng Meng
Fang Liu
Ping Che
Yanxin Zhang
Ying Wang
Li Cai
Wen Qin
Nan Zhang
author_facet Jing Xu
Yanmin Xia
Meng Meng
Fang Liu
Ping Che
Yanxin Zhang
Ying Wang
Li Cai
Wen Qin
Nan Zhang
author_sort Jing Xu
collection DOAJ
description Abstract Background Semantic variant primary progressive aphasia (svPPA) is generally sporadic, with very few reports of tau pathology caused by MAPT mutations. Methods A 64-year-old man was diagnosed with svPPA with MAPT P301L mutation. Clinical information, cognitive and language functions, multimodal magnetic resonance imaging (MRI), blood biomarkers, fluorodeoxyglucose (FDG) imaging and tau positron emission tomography (PET) were obtained. Results Semantic memory impairment was the earliest and most prominent symptom in this family. Tau accumulation and hypometabolism were observed prior to brain atrophy in mutation carriers. Plasma NfL and GFAP concentrations were elevated in the two svPPA patients. Some relative decreases and some relative increases in regional cerebral blood flow (CBF) as measured by arterial spin labelling (ASL) were observed in mutation carriers compared to noncarriers. Conclusions This study describes a large svPPA-affected family with the MAPT P301L mutation and provides an ideal model for inferring underlying pathology and pathophysiological processes in svPPA caused by tauopathies.
first_indexed 2024-04-10T19:45:47Z
format Article
id doaj.art-e389ecd79dd845d8bef51154557d6204
institution Directory Open Access Journal
issn 1758-9193
language English
last_indexed 2024-04-10T19:45:47Z
publishDate 2023-01-01
publisher BMC
record_format Article
series Alzheimer’s Research & Therapy
spelling doaj.art-e389ecd79dd845d8bef51154557d62042023-01-29T12:06:11ZengBMCAlzheimer’s Research & Therapy1758-91932023-01-0115111410.1186/s13195-023-01176-yClinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutationJing Xu0Yanmin Xia1Meng Meng2Fang Liu3Ping Che4Yanxin Zhang5Ying Wang6Li Cai7Wen Qin8Nan Zhang9Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General HospitalDepartment of Neurology, Tianjin Neurological Institute, Tianjin Medical University General HospitalDepartment of Neurology, Tianjin Medical University General Hospital Airport SiteDepartment of Neurology, Tianjin Neurological Institute, Tianjin Medical University General HospitalDepartment of Neurology, Tianjin Neurological Institute, Tianjin Medical University General HospitalDepartment of Neurology, Tianjin Neurological Institute, Tianjin Medical University General HospitalDepartment of PET-CT Diagnostic, Tianjin Medical University General HospitalDepartment of PET-CT Diagnostic, Tianjin Medical University General HospitalDepartment of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General HospitalDepartment of Neurology, Tianjin Neurological Institute, Tianjin Medical University General HospitalAbstract Background Semantic variant primary progressive aphasia (svPPA) is generally sporadic, with very few reports of tau pathology caused by MAPT mutations. Methods A 64-year-old man was diagnosed with svPPA with MAPT P301L mutation. Clinical information, cognitive and language functions, multimodal magnetic resonance imaging (MRI), blood biomarkers, fluorodeoxyglucose (FDG) imaging and tau positron emission tomography (PET) were obtained. Results Semantic memory impairment was the earliest and most prominent symptom in this family. Tau accumulation and hypometabolism were observed prior to brain atrophy in mutation carriers. Plasma NfL and GFAP concentrations were elevated in the two svPPA patients. Some relative decreases and some relative increases in regional cerebral blood flow (CBF) as measured by arterial spin labelling (ASL) were observed in mutation carriers compared to noncarriers. Conclusions This study describes a large svPPA-affected family with the MAPT P301L mutation and provides an ideal model for inferring underlying pathology and pathophysiological processes in svPPA caused by tauopathies.https://doi.org/10.1186/s13195-023-01176-yFrontotemporal lobar degenerationSemantic variant primary progressive aphasiaMAPT geneP301L mutationNext-generation sequencing
spellingShingle Jing Xu
Yanmin Xia
Meng Meng
Fang Liu
Ping Che
Yanxin Zhang
Ying Wang
Li Cai
Wen Qin
Nan Zhang
Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
Alzheimer’s Research & Therapy
Frontotemporal lobar degeneration
Semantic variant primary progressive aphasia
MAPT gene
P301L mutation
Next-generation sequencing
title Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
title_full Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
title_fullStr Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
title_full_unstemmed Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
title_short Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation
title_sort clinical features and biomarkers of semantic variant primary progressive aphasia with mapt mutation
topic Frontotemporal lobar degeneration
Semantic variant primary progressive aphasia
MAPT gene
P301L mutation
Next-generation sequencing
url https://doi.org/10.1186/s13195-023-01176-y
work_keys_str_mv AT jingxu clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT yanminxia clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT mengmeng clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT fangliu clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT pingche clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT yanxinzhang clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT yingwang clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT licai clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT wenqin clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation
AT nanzhang clinicalfeaturesandbiomarkersofsemanticvariantprimaryprogressiveaphasiawithmaptmutation